U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H46O
Molecular Weight 326.6
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Docosanol

SMILES

CCCCCCCCCCCCCCCCCCCCCCO

InChI

InChIKey=NOPFSRXAKWQILS-UHFFFAOYSA-N
InChI=1S/C22H46O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23/h23H,2-22H2,1H3

HIDE SMILES / InChI

Molecular Formula C22H46O
Molecular Weight 326.6
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including

Docosanol is a saturated 22-carbon aliphatic alcohol which exhibits antiviral activity against many lipid enveloped viruses including herpes simplex virus (HSV). Docosanol speeds the healing of cold sores and fever blisters on the face or lips. It also relieves the accompanying symptoms, including tingling, pain, burning, and itching. Docosanol works by inhibiting fusion between the human cell plasma membrane and the herpes simplex virus (HSV) envelope, thereby preventing viral entry into cells and subsequent viral replication. Unlike other cold-sore antivirals, docosanol does not act directly on the virus, and as such it is unlikely it will produce drug resistant mutants of HSV. Used for the topical treatment of recurrent oral-facial herpes simplex episodes (cold sores or fever blisters).

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
10.0 mM [EC50]
Target ID: P03200
Gene ID: 3783713.0
Gene Symbol: NA
Target Organism: Epstein-Barr virus (strain B95-8) (HHV-4) (Human herpesvirus 4)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Abreva

Approved Use

Herpes Labialis Topical treatment of recurrent herpes labialis (perioral herpes, cold sores, fever blisters)

Launch Date

2000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
318 ng/mL
5 g single, oral
dose: 5 g
route of administration: Oral
experiment type: SINGLE
co-administered:
DOCOSANOL plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
10 % 5 times / day steady, topical
Recommended
Dose: 10 %, 5 times / day
Route: topical
Route: steady
Dose: 10 %, 5 times / day
Sources:
unhealthy, 18-77 years
Health Status: unhealthy
Age Group: 18-77 years
Sex: M+F
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as victim
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Nongenital herpes simplex virus.
2010-11-01
Soybean metabolites regulated in root hairs in response to the symbiotic bacterium Bradyrhizobium japonicum.
2010-08
LAP5 and LAP6 encode anther-specific proteins with similarity to chalcone synthase essential for pollen exine development in Arabidopsis.
2010-07
Rapid sampling of molecules via skin for diagnostic and forensic applications.
2010-07
A Potent, Broad-Spectrum Antiviral Agent that Targets Viral Membranes.
2010-05
Topical n-docosanol for management of recurrent herpes labialis.
2010-04
An ethnobotanical survey of medicinal plants in Babungo, Northwest Region, Cameroon.
2010-02-15
Nutritional bioactive components of wheat straw as affected by genotype and environment.
2010-01
Effect of combinations of antiviral drugs on herpes simplex encephalitis.
2009-12-29
Drugs associated with more suicidal ideations are also associated with more suicide attempts.
2009-10-02
[Study on the chemical constituents from Clematis brevicaudata].
2009-10
Comments on study of paw pad lesions in dogs.
2009-09-15
[Tadenan treatment of prostatic adenoma].
2009-06-17
Docosanol: new drug. Herpes labialis: barely more effective than an excipient.
2009-06
Policosanol, alpha-tocopherol, and moisture content as a function of timing of harvest of Switchgrass (Panicum virgatum L.).
2009-05-13
[Efficacy of tadenan in chronic prostatitis complicated by sterility].
2008-12-06
Phytotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia.
2008-06
Single-day treatment for orolabial and genital herpes: a brief review of pathogenesis and pharmacology.
2008-04
Expression of transforming growth factor beta1 gene, basic fibroblast growth factor gene and hydroxyproline in diabetes-induced bladder dysfunction in a rat model.
2008
Management and prevention of recurrent herpes labialis in immunocompetent patients.
2007-12
Alpha-glucosidase inhibitors from Millettia conraui.
2007-09
Management of recurrent oral herpes simplex infections.
2007-03
[Studies on the chemical constituents of the aerial parts of Seseli mairei].
2007-01
Structure and performance of cationic assembly dispersed in amphoteric surfactants solution as a shampoo for hair damaged by coloring.
2007
The lipid polyester composition of Arabidopsis thaliana and Brassica napus seeds.
2006-12
Weak first-order tilting transition in monolayers of mono- and bipolar docosanol derivatives.
2006-11-09
Self-assembled two-dimensional ordered arrays of tripod-type molecules on graphite.
2006-07-04
New antiviral agents.
2006-04
Two-dimensional miscibility studies--the analysis of interaction between long-chain alcohols and semifluorinated alkanes.
2006-02-23
[Modern pharmacotherapy of benign prostatic hyperplasia].
2005-11
Low-dose tadenan protects the rabbit bladder from bilateral ischemia/ reperfusion-induced contractile dysfunction.
2005-01
Docosanol: a topical antiviral for herpes labialis.
2004-12
[Tadenan (Pygeum africanum extract) in the treatment of patients with benign prostatic hyperplasia].
2004-11-25
Therapeutic options for herpes labialis, II: Topical agents.
2004-07
Two-dimensional packing patterns of amino acid surfactant and higher alcohols in an aqueous phase and their associated packing parameters.
2004-05-15
Molecular transfer and transport in noncovalent microcontact printing.
2004-02-03
Effect of topically applied resveratrol on cutaneous herpes simplex virus infections in hairless mice.
2004-01
Constituents of Hypericum laricifolium and their cyclooxygenase (COX) enzyme activities.
2003-12
Efficacy of docosanol.
2003-09
Cytotoxic activity of the root extract from Myoschilos oblongum.
2003-07
Effect of Pygeum africanum tadenan on micturition and prostate growth of the rat secondary to coadministered treatment and post-treatment with dihydrotestosterone.
2003-02
Study of detrusor dysfunction due to outlet obstruction: link between analysis of uroflows of men with benign prostatic hyperplasia and animal studies.
2003
Synergistic inhibition of herpesvirus replication by docosanol and antiviral nucleoside analogs.
2002-11
Inhibition of type 1 and type 2 5alpha-reductase activity by free fatty acids, active ingredients of Permixon.
2002-10
N-docosanol (Abreva) for herpes labialis: problems and questions.
2002-09
The toxicity of behenyl alcohol. II. Reproduction studies in rats and rabbits.
2002-08
The toxicity of behenyl alcohol. I. Genotoxicity and subchronic toxicity in rats and dogs.
2002-08
New drug approvals in 2000.
2002-05-23
n-Docosanol inhibits in vitro replication of HIV and other retroviruses.
1996-01-01
Antiviral activity of 1-docosanol, an inhibitor of lipid-enveloped viruses including herpes simplex.
1991-12-01
Patents

Sample Use Guides

Apply docosanol topical in a quantity sufficient to cover the affected lesions and immediately surrounding skin five times a day until the lesions are healed.
Route of Administration: Topical
In Vitro Use Guide
31 mM docosanol inhibited HIV-1 replication up to 82%
Substance Class Chemical
Created
by admin
on Mon Mar 31 21:26:28 GMT 2025
Edited
by admin
on Mon Mar 31 21:26:28 GMT 2025
Record UNII
9G1OE216XY
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
Docosanol
HSDB   II   MART.   ORANGE BOOK   USAN   VANDF   WHO-DD  
USAN  
Official Name English
Behenyl alcohol
INCI  
INCI  
Preferred Name English
NSC-8407
Code English
Docosanol [WHO-DD]
Common Name English
1-Docosanol
Systematic Name English
N-Docosanol
MI  
Common Name English
Docosanol [ORANGE BOOK]
Common Name English
Behenic alcohol
Common Name English
Docosanol [MART.]
Common Name English
Docosanol [VANDF]
Common Name English
Docosanol [HSDB]
Common Name English
N-Docosanol [MI]
Common Name English
STENOL 1822
Brand Name English
Abreva
Brand Name English
Docosanol [USAN]
Common Name English
Docosanol [II]
Common Name English
Classification Tree Code System Code
WHO-ATC D06BB11
Created by admin on Mon Mar 31 21:26:28 GMT 2025 , Edited by admin on Mon Mar 31 21:26:28 GMT 2025
WHO-VATC QD06BB11
Created by admin on Mon Mar 31 21:26:28 GMT 2025 , Edited by admin on Mon Mar 31 21:26:28 GMT 2025
NCI_THESAURUS C281
Created by admin on Mon Mar 31 21:26:28 GMT 2025 , Edited by admin on Mon Mar 31 21:26:28 GMT 2025
Code System Code Type Description
CAS
661-19-8
Created by admin on Mon Mar 31 21:26:28 GMT 2025 , Edited by admin on Mon Mar 31 21:26:28 GMT 2025
PRIMARY
EPA CompTox
DTXSID4027286
Created by admin on Mon Mar 31 21:26:28 GMT 2025 , Edited by admin on Mon Mar 31 21:26:28 GMT 2025
PRIMARY
FDA UNII
9G1OE216XY
Created by admin on Mon Mar 31 21:26:28 GMT 2025 , Edited by admin on Mon Mar 31 21:26:28 GMT 2025
PRIMARY
SMS_ID
100000088244
Created by admin on Mon Mar 31 21:26:28 GMT 2025 , Edited by admin on Mon Mar 31 21:26:28 GMT 2025
PRIMARY
MERCK INDEX
m4714
Created by admin on Mon Mar 31 21:26:28 GMT 2025 , Edited by admin on Mon Mar 31 21:26:28 GMT 2025
PRIMARY Merck Index
DRUG BANK
DB00632
Created by admin on Mon Mar 31 21:26:28 GMT 2025 , Edited by admin on Mon Mar 31 21:26:28 GMT 2025
PRIMARY
ChEMBL
CHEMBL1200453
Created by admin on Mon Mar 31 21:26:28 GMT 2025 , Edited by admin on Mon Mar 31 21:26:28 GMT 2025
PRIMARY
DRUG CENTRAL
940
Created by admin on Mon Mar 31 21:26:28 GMT 2025 , Edited by admin on Mon Mar 31 21:26:28 GMT 2025
PRIMARY
NCI_THESAURUS
C47498
Created by admin on Mon Mar 31 21:26:28 GMT 2025 , Edited by admin on Mon Mar 31 21:26:28 GMT 2025
PRIMARY
CHEBI
31000
Created by admin on Mon Mar 31 21:26:28 GMT 2025 , Edited by admin on Mon Mar 31 21:26:28 GMT 2025
PRIMARY
DAILYMED
9G1OE216XY
Created by admin on Mon Mar 31 21:26:28 GMT 2025 , Edited by admin on Mon Mar 31 21:26:28 GMT 2025
PRIMARY
NSC
8407
Created by admin on Mon Mar 31 21:26:28 GMT 2025 , Edited by admin on Mon Mar 31 21:26:28 GMT 2025
PRIMARY
CAS
30303-65-2
Created by admin on Mon Mar 31 21:26:28 GMT 2025 , Edited by admin on Mon Mar 31 21:26:28 GMT 2025
NON-SPECIFIC SUBSTITUTION
RXCUI
594680
Created by admin on Mon Mar 31 21:26:28 GMT 2025 , Edited by admin on Mon Mar 31 21:26:28 GMT 2025
PRIMARY RxNorm
PUBCHEM
12620
Created by admin on Mon Mar 31 21:26:28 GMT 2025 , Edited by admin on Mon Mar 31 21:26:28 GMT 2025
PRIMARY
HSDB
5739
Created by admin on Mon Mar 31 21:26:28 GMT 2025 , Edited by admin on Mon Mar 31 21:26:28 GMT 2025
PRIMARY
USAN
LL-43
Created by admin on Mon Mar 31 21:26:28 GMT 2025 , Edited by admin on Mon Mar 31 21:26:28 GMT 2025
PRIMARY
EVMPD
SUB21986
Created by admin on Mon Mar 31 21:26:28 GMT 2025 , Edited by admin on Mon Mar 31 21:26:28 GMT 2025
PRIMARY
WIKIPEDIA
DOCOSANOL
Created by admin on Mon Mar 31 21:26:28 GMT 2025 , Edited by admin on Mon Mar 31 21:26:28 GMT 2025
PRIMARY
ECHA (EC/EINECS)
211-546-6
Created by admin on Mon Mar 31 21:26:28 GMT 2025 , Edited by admin on Mon Mar 31 21:26:28 GMT 2025
PRIMARY
Related Record Type Details
ACTIVE MOIETY